My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 119

    1.

    Effects of tamoxifen on cardiovascular risk factors in postmenopausal women.

    Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, Feyzi J, DeMets DL.

    Ann Intern Med. 1991 Dec 1;115(11):860-4.PMID: 1952472 [PubMed - indexed for MEDLINE]Related articles

    2.

    Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment.

    Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ.

    J Natl Cancer Inst. 1994 Oct 19;86(20):1534-9.PMID: 7932809 [PubMed - indexed for MEDLINE]Related articles

    3.

    The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.

    Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R.

    Ann Oncol. 2004 Feb;15(2):211-7.PMID: 14760111 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer.

    Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, DeMets DL.

    J Natl Cancer Inst. 1990 Aug 15;82(16):1327-32.PMID: 2199681 [PubMed - indexed for MEDLINE]Related articles

    5.

    A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.

    Kakis G, Powell M, Marshall A, Woutersz TB, Steiner G.

    Int J Fertil Menopausal Stud. 1994 Sep-Oct;39(5):283-91.PMID: 7820162 [PubMed - indexed for MEDLINE]Related articles

    6.

    Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.

    Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM.

    Ann Intern Med. 1996 Oct 1;125(7):529-40.PMID: 8815751 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Effects of hormone replacement therapy on serum lipids in elderly women. a randomized, placebo-controlled trial.

    Binder EF, Williams DB, Schechtman KB, Jeffe DB, Kohrt WM.

    Ann Intern Med. 2001 May 1;134(9 Pt 1):754-60.PMID: 11329233 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).

    Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, Perez EA.

    Ann Oncol. 2005 May;16(5):707-15. Epub 2005 Apr 7.PMID: 15817595 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes?

    Liberopoulos E, Karabina SA, Tselepis A, Bairaktari E, Nicolaides C, Pavlidis N, Elisaf M.

    Oncology. 2002;62(2):115-20.PMID: 11914596 [PubMed - indexed for MEDLINE]Related articles

    10.

    Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.

    [No authors listed]

    JAMA. 1995 Jan 18;273(3):199-208. Erratum in: JAMA 1995 Dec 6;274(21):1676. PMID: 7807658 [PubMed - indexed for MEDLINE]Related articles

    11.

    Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.

    Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE.

    JAMA. 2005 Jul 20;294(3):326-33.PMID: 16030277 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Administration of long-term tamoxifen therapy modifies the plasma lipoprotein-lipid concentration and lipid transfer protein I activity in postmenopausal women with breast cancer.

    Wasan KM, Ramaswamy M, Haley J, Dunn BP.

    J Pharm Sci. 1997 Jul;86(7):876-9.PMID: 9232532 [PubMed - indexed for MEDLINE]Related articles

    13.

    Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status.

    Ilanchezhian S, Thangaraju M, Sachdanandam P.

    Cancer Biochem Biophys. 1995 Nov;15(2):83-90.PMID: 8590439 [PubMed - indexed for MEDLINE]Related articles

    14.

    Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.

    Akerlund M, Almström E, Högstedt S, Nabrink M.

    Acta Obstet Gynecol Scand. 1994 Feb;73(2):136-43.PMID: 8116352 [PubMed - indexed for MEDLINE]Related articles

    15.

    Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.

    Esteva FJ, Hortobagyi GN.

    Breast. 2006 Jun;15(3):301-12. Epub 2005 Oct 17. Review.PMID: 16230014 [PubMed - indexed for MEDLINE]Related articles

    16.

    Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.

    Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I.

    J Clin Oncol. 1996 Feb;14(2):429-33.PMID: 8636753 [PubMed - indexed for MEDLINE]Related articles

    17.

    Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer.

    Thangaraju M, Kumar K, Gandhirajan R, Sachdanandam P.

    Cancer. 1994 Feb 1;73(3):659-63.PMID: 8299087 [PubMed - indexed for MEDLINE]Related articles

    18.

    Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr.

    JAMA. 1998 May 27;279(20):1615-22.PMID: 9613910 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.

    Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, Lappas H, Gogas H.

    Breast Cancer Res Treat. 2005 Sep;93(1):61-6.PMID: 16184460 [PubMed - indexed for MEDLINE]Related articles

    20.

    Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study.

    Taechakraichana N, Holinka CF, Haines CJ, Subramaniam R, Tian XW, Ausmanas MK.

    Climacteric. 2007 Jun;10(3):225-37.PMID: 17487649 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity